<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35367865</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2104</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>605</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical and biophysical research communications</Title>
          <ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evidence for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19.</ArticleTitle>
        <Pagination>
          <StartPage>171</StartPage>
          <EndPage>176</EndPage>
          <MedlinePgn>171-176</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2022.03.035</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(22)00360-6</ELocationID>
        <Abstract>
          <AbstractText>A key component of severe COVID-19 is a "cytokine storm" i.e., the excessive expression of unneeded cytokines. Previous studies suggest that SARS-CoV-2 proteins can induce macrophages to secrete pro-inflammatory cytokines; a process that may involve Toll-like receptors (TLRs). Glycogen synthase kinase-3 (GSK-3) has been implicated in TLR signal transduction and a selective GSK-3 inhibitor, termed COB-187, dramatically attenuates cytokine expression induced by the TLR ligand lipopolysaccharide (LPS). In the present study, we provide evidence that the SARS-CoV-2 spike protein (S) and the S2 subunit (S2) induce production of CXCL10 (a chemokine elevated in severe COVID-19) by a human macrophage cell line. Further, we report that two clinically relevant GSK-3 inhibitors and COB-187 attenuate S and S2 protein-induced CXCL10 production. Combined, our observations provide impetus for investigating GSK-3 inhibitors as potential therapeutics for severe COVID-19.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ghazanfari</LastName>
            <ForeName>Davoud</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Courreges</LastName>
            <ForeName>Maria Cecilia</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Specialty Medicine, Ohio University, Athens, OH, 45701, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Belinski</LastName>
            <ForeName>Lydia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bergmeier</LastName>
            <ForeName>Stephen C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Engineering Program, Ohio University, Athens, OH, 45701, United States; Department of Chemistry and Biochemistry, Ohio University, Athens, OH, 45701, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McCall</LastName>
            <ForeName>Kelly D</ForeName>
            <Initials>KD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Specialty Medicine, Ohio University, Athens, OH, 45701, United States; Biomedical Engineering Program, Ohio University, Athens, OH, 45701, United States; The Diabetes Institute, Ohio University, Athens, OH, 45701, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goetz</LastName>
            <ForeName>Douglas J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, United States; Biomedical Engineering Program, Ohio University, Athens, OH, 45701, United States. Electronic address: goetzd@ohio.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R15 GM110602</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
        <NlmUniqueID>0372516</NlmUniqueID>
        <ISSNLinking>0006-291X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.26</RegistryNumber>
          <NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D038362" MajorTopicYN="Y">Glycogen Synthase Kinase 3</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">CXCL10</Keyword>
        <Keyword MajorTopicYN="Y">Cytokine storm</Keyword>
        <Keyword MajorTopicYN="Y">Glycogen synthase kinase-3</Keyword>
        <Keyword MajorTopicYN="Y">Spike protein</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest Ohio University owns patents related to COB-187. SCB, KDM, and DJG are inventors on the patents.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>20</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35367865</ArticleId>
        <ArticleId IdType="pmc">PMC8924054</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbrc.2022.03.035</ArticleId>
        <ArticleId IdType="pii">S0006-291X(22)00360-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fajgenbaum D.C., June C.H. Cytokine storm. N. Engl. J. Med. 2020;383:2255–2273. doi: 10.1056/NEJMRA2026131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMRA2026131</ArticleId>
            <ArticleId IdType="pmc">PMC7727315</ArticleId>
            <ArticleId IdType="pubmed">33264547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newton K., Dixit V.M. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect. Biol. 2012;4:a006049. doi: 10.1101/CSHPERSPECT.A006049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/CSHPERSPECT.A006049</ArticleId>
            <ArticleId IdType="pmc">PMC3282411</ArticleId>
            <ArticleId IdType="pubmed">22296764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satarker S., Nampoothiri M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch. Med. Res. 2020;51:482–491. doi: 10.1016/j.arcmed.2020.05.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arcmed.2020.05.012</ArticleId>
            <ArticleId IdType="pmc">PMC7247499</ArticleId>
            <ArticleId IdType="pubmed">32493627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan S., Shafiei M.S., Longoria C., Schoggins J.W., Savani R.C., Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife. 2021;10 doi: 10.7554/ELIFE.68563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/ELIFE.68563</ArticleId>
            <ArticleId IdType="pmc">PMC8709575</ArticleId>
            <ArticleId IdType="pubmed">34866574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng M., Karki R., Williams E.P., Yang D., Fitzpatrick E., Vogel P., Jonsson C.B., Kanneganti T.D. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 2021;22:829–838. doi: 10.1038/s41590-021-00937-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId>
            <ArticleId IdType="pmc">PMC8882317</ArticleId>
            <ArticleId IdType="pubmed">33963333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karwaciak I., Sałkowska A., Karaś K., Dastych J., Ratajewski M. Nucleocapsid and spike proteins of the coronavirus SARS-CoV-2 induce IL6 in monocytes and macrophages—potential implications for cytokine storm syndrome. Vaccines. 2021;9:1–10. doi: 10.3390/vaccines9010054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines9010054</ArticleId>
            <ArticleId IdType="pmc">PMC7830532</ArticleId>
            <ArticleId IdType="pubmed">33467724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirato K., Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon. 2021;7 doi: 10.1016/J.HELIYON.2021.E06187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.HELIYON.2021.E06187</ArticleId>
            <ArticleId IdType="pmc">PMC7887388</ArticleId>
            <ArticleId IdType="pubmed">33644468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiok K., Hutchison K., Miller L.G., Bose S., Miura T.A. Proinflammatory responses in SARS-CoV-2 infected and soluble spike glycoprotein S1 subunit activated human macrophages, bioRxiv. Preprint. 2021 doi: 10.1101/2021.06.14.448426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.06.14.448426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y., Kuang M., Li J., Zhu L., Jia Z., Guo X., Hu Y., Kong J., Yin H., Wang X., You F. SARS-CoV-2 spike protein interacts with and activates TLR4. Cell Res. 2021;31:818–820. doi: 10.1038/S41422-021-00495-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/S41422-021-00495-9</ArticleId>
            <ArticleId IdType="pmc">PMC7975240</ArticleId>
            <ArticleId IdType="pubmed">33742149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantazi I., Al-Qahtani A.A., Alhamlan F.S., Alothaid H., Matou-Nasri S., Sourvinos G., Vergadi E., Tsatsanis C. SARS-CoV-2/ACE2 interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages. Front. Immunol. 2021;12:683800. doi: 10.3389/FIMMU.2021.683800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FIMMU.2021.683800</ArticleId>
            <ArticleId IdType="pmc">PMC8261299</ArticleId>
            <ArticleId IdType="pubmed">34248968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowaiye A.B., Okpalefe O.A., Adejoke O.O., Ogidigo J.O., Oladipo O.H., Ogu A.C., Oli A.N., Olofinase S., Onyekwere O., Abubakar A.R., Jahan D., Islam S., Dutta S., Haque M. Attenuating the effects of novel COVID-19 (SARS-CoV-2) infection-induced cytokine storm and the implications. J. Inflamm. Res. 2021;14:1487–1510. doi: 10.2147/JIR.S301784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JIR.S301784</ArticleId>
            <ArticleId IdType="pmc">PMC8057798</ArticleId>
            <ArticleId IdType="pubmed">33889008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001;2:769–776. doi: 10.1038/35096075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35096075</ArticleId>
            <ArticleId IdType="pubmed">11584304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9(8):2431–2438. doi: 10.1002/j.1460-2075.1990.tb07419.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/j.1460-2075.1990.tb07419.x</ArticleId>
            <ArticleId IdType="pmc">PMC552268</ArticleId>
            <ArticleId IdType="pubmed">2164470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1976;68:31–44. doi: 10.1111/j.1432-1033.1980.tb06059.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1432-1033.1980.tb06059.x</ArticleId>
            <ArticleId IdType="pubmed">6249596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 2005;6(8):777–784. doi: 10.1038/ni1221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1221</ArticleId>
            <ArticleId IdType="pmc">PMC1933525</ArticleId>
            <ArticleId IdType="pubmed">16007092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saraswati A.P., Ali Hussaini S.M., Krishna N.H., Babu B.N., Kamal A. Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions. Eur. J. Med. Chem. 2018;144:843–858. doi: 10.1016/j.ejmech.2017.11.103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2017.11.103</ArticleId>
            <ArticleId IdType="pubmed">29306837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noori M.S., Courreges M.C., Bergmeier S.C., McCall K.D., Goetz D.J. Modulation of LPS-induced inflammatory cytokine production by a novel glycogen synthase kinase-3 inhibitor. Eur. J. Pharmacol. 2020;883:173340. doi: 10.1016/j.ejphar.2020.173340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2020.173340</ArticleId>
            <ArticleId IdType="pmc">PMC7334664</ArticleId>
            <ArticleId IdType="pubmed">32634441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noori M.S., Bhatt P.M., Courreges M.C., Ghazanfari D., Cuckler C., Orac C.M., McMills M.C., Schwartz F.L., Deosarkar S.P., Bergmeier S.C., McCall K.D., Goetz D.J. Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3. Am. J. Physiol. Cell Physiol. 2019;317:C1289–C1303. doi: 10.1152/ajpcell.00061.2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00061.2019</ArticleId>
            <ArticleId IdType="pmc">PMC6962522</ArticleId>
            <ArticleId IdType="pubmed">31553649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng C., Chen J., Chu F., Zhu J., Jin T. Inflammatory role of TLR-MyD88 signaling in multiple sclerosis. Front. Mol. Neurosci. 2020;12:314. doi: 10.3389/FNMOL.2019.00314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FNMOL.2019.00314</ArticleId>
            <ArticleId IdType="pmc">PMC6965019</ArticleId>
            <ArticleId IdType="pubmed">31998072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyle S.E., Vaidya S.A., O'Connell R., Dadgostar H., Dempsey P.W., Wu T.T., Rao G., Sun R., Haberland M.E., Modlin R.L., Cheng G. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 2002;17:251–263. doi: 10.1016/S1074-7613(02)00390-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1074-7613(02)00390-4</ArticleId>
            <ArticleId IdType="pubmed">12354379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coperchini F., Chiovato L., Rotondi M. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: not one for all but all for one. Front. Immunol. 2021;12:668507. doi: 10.3389/FIMMU.2021.668507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/FIMMU.2021.668507</ArticleId>
            <ArticleId IdType="pmc">PMC8107352</ArticleId>
            <ArticleId IdType="pubmed">33981314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaikwad S., Agrawal-Rajput R. Lipopolysaccharide from rhodobacter sphaeroides attenuates microglia-mediated inflammation and phagocytosis and directs regulatory T Cell response. Int. J. Inflamm. 2015:361326. doi: 10.1155/2015/361326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/361326</ArticleId>
            <ArticleId IdType="pmc">PMC4589630</ArticleId>
            <ArticleId IdType="pubmed">26457222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carneiro B.A., Cavalcante L., Bastos B.R., Powell S.F., Ma W.W., Sahebjam S., Harvey D., De Souza A.L., Dhawan M.S., Safran H., Giles F.J., Munster P.N. Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. J. Clin. Oncol. 2020;38 doi: 10.1200/jco.2020.38.15_suppl.3507. 3507–3507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2020.38.15_suppl.3507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurgan N., Whitley K.C., Maddalena L.A., Moradi F., Stoikos J., Hamstra S.I., Rubie E.A., Kumar M., Roy B.D., Woodgett J.R., Stuart J.A., Fajardo V.A. A Low-therapeutic dose of lithium inhibits GSK3 and enhances myoblast fusion in C2C12 cells. Cells. 2019;8(11):1340. doi: 10.3390/CELLS8111340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/CELLS8111340</ArticleId>
            <ArticleId IdType="pmc">PMC6912290</ArticleId>
            <ArticleId IdType="pubmed">31671858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A Study of LY2090314 and chemotherapy in participants with metastatic pancreatic cancer. 2015. https://clinicaltrials.gov/ct2/show/NCT01632306</Citation>
        </Reference>
        <Reference>
          <Citation>Lovestone S., Boada M., Dubois B., Hüll M., Rinne J.O., Huppertz H.J., Calero M., Andrés M.V., Gómez-Carrillo B., León T., Del Ser T. A phase II trial of tideglusib in Alzheimer's disease. J. Alzheim. Dis. 2015;45(1):75–88. doi: 10.3233/JAD-141959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-141959</ArticleId>
            <ArticleId IdType="pubmed">25537011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georgievska B., Sandin J., Doherty J., Mörtberg A., Neelissen J., Andersson A., Gruber S., Nilsson Y., Schött P., Arvidsson P.I., Hellberg S., Osswald G., Berg S., Fälting J., Bhat R.V. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J. Neurochem. 2013;125:446–456. doi: 10.1111/jnc.12203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.12203</ArticleId>
            <ArticleId IdType="pubmed">23410232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghazanfari D., Noori M.S., Bergmeier S.C., Hines J.V., McCall K.D., Goetz D.J. A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism. Bioorg. Med. Chem. 2021;40:116179. doi: 10.1016/J.BMC.2021.116179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.BMC.2021.116179</ArticleId>
            <ArticleId IdType="pmc">PMC8972088</ArticleId>
            <ArticleId IdType="pubmed">33991821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharun K., Tiwari R., Dhama J., Dhama K. Dexamethasone to combat cytokine storm in COVID-19: clinical trials and preliminary evidence. Int. J. Surg. 2020;82:179–181. doi: 10.1016/J.IJSU.2020.08.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/J.IJSU.2020.08.038</ArticleId>
            <ArticleId IdType="pmc">PMC7472975</ArticleId>
            <ArticleId IdType="pubmed">32896649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grallert H., Leopoldseder S., Schuett M., Kurze P., Buchberger B. EndoLISA®: a novel and reliable method for endotoxin detection. Nat. Methods. 2011;8 doi: 10.1038/nmeth.f.350. iii–v.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.f.350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsan M.-F., Gao B. Heat shock proteins and immune system. J. Leukoc. Biol. 2009;85:905–910. doi: 10.1189/JLB.0109005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/JLB.0109005</ArticleId>
            <ArticleId IdType="pubmed">19276179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso L.S., Araujo M.I., Góes A.M., Pacífico L.G., Oliveira R.R., Oliveira S.C. Polymyxin B as inhibitor of LPS contamination of schistosoma mansoni recombinant proteins in human cytokine analysis. Microb. Cell Factories. 2007;6:1. doi: 10.1186/1475-2859-6-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1475-2859-6-1</ArticleId>
            <ArticleId IdType="pmc">PMC1766364</ArticleId>
            <ArticleId IdType="pubmed">17201926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukherjee S., Chen L.Y., Papadimos T.J., Huang S., Zuraw B.L., Pan Z.K. Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. J. Biol. Chem. 2009;284:29391–29398. doi: 10.1074/JBC.M109.005272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/JBC.M109.005272</ArticleId>
            <ArticleId IdType="pmc">PMC2785571</ArticleId>
            <ArticleId IdType="pubmed">19638630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirshenboim N., Plotkin B., Ben Shlomo S., Kaidanovich-Beilin O., Eldar-Finkelman H. Lithium-mediated phosphorylation of glycogen synthase kinase-3β involves PI3 kinase-dependent activation of protein kinase C-α. J. Mol. Neurosci. 2004;24:237–245. doi: 10.1385/JMN:24:2:237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1385/JMN:24:2:237</ArticleId>
            <ArticleId IdType="pubmed">15456937</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
